NCT05885048 Impact of Gonadotoxic Therapies on Fertility
| NCT ID | NCT05885048 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Michael von Wolff |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 7,000 participants |
| Start Date | 2023-12-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7,000 participants in total. It began in 2023-12-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer. The main questions it aims to answer are: * in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve); * in males, if cancer therapies reduce sperm concentration (sperm quality).
Eligibility Criteria
Inclusion Criteria: * Patients with cancer or with benign reasons undergoing chemotherapy and/or radiotherapy of the pelvis (females) and the testicles (males) and/or immune therapy; * Willing to participate; * Austria: 14-50 years old (adolescents and adults), Germany: 18-50 years old, Switzerland: 14-50 years old (adolescents and adults); * Serum hormone analysis before gonadotoxic therapy (females) or serum hormone analysis and sperm analysis before gonadotoxic therapy (males). Exclusion Criteria: * Missing consent; * Language barrier.
Contact & Investigator
Michael von Wolff, Prof. Dr.
PRINCIPAL INVESTIGATOR
Insel Gruppe AG, University Hospital Bern
Frequently Asked Questions
Who can join the NCT05885048 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 50 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05885048 currently recruiting?
Yes, NCT05885048 is actively recruiting participants. Contact the research team at michael.vonwolff@insel.ch for enrollment information.
Where is the NCT05885048 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT05885048 clinical trial?
NCT05885048 is sponsored by Michael von Wolff. The principal investigator is Michael von Wolff, Prof. Dr. at Insel Gruppe AG, University Hospital Bern. The trial plans to enroll 7,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.